Resources
187 Results (showing 1 - 10)
Results sorted by updated date (newest first)
Results sorted by updated date (newest first)
Posted 5/3/2021 (updated 4/10/2024)
The U.S. Food and Drug Administration (FDA) announced on April 30, 2021 the approval of a higher dose naloxone hydrochloride nasal spray product to treat opioid overdose. The newly approved product delivers 8 milligrams (mg) of naloxone into the nasal cavity. The FDA had previously approved 2 mg and 4 mg naloxone nasal spray products.
Naloxone is a medicine that can be administered by individuals with or without medical training to help reduce opioid overdose deaths. If naloxone is administered quickly, it can counter the opioid overdose effects, usually within minutes. A higher dose of naloxone provides an additional option in the treatment of opioid overdoses.
Posted 4/26/2021 (updated 4/10/2024)
The Evidence-Based Resource Guide Series is a comprehensive set of modules with resources to improve health outcomes for people at risk for, with, or recovering from mental and/or substance use disorders. It is designed for practitioners, administrators, community leaders, and others considering an intervention for their organization or community.
Posted 4/1/2024 (updated 4/5/2024)
Below is a listing of the sessions that occurred at the 2024 Reverse Site Visit on Friday, March 8, 2024 from 9:45 a.m. - 11:15 a.m. Click on a link to access the session's materials.
Posted 3/29/2024 (updated 4/4/2024)
Posted 3/29/2024 (updated 4/4/2024)
Posted 3/29/2024 (updated 4/4/2024)
Posted 3/29/2024 (updated 4/4/2024)
Posted 3/29/2024 (updated 4/4/2024)